All Stories

  1. Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH
  2. Therapeutic Application of mRNA for Genetic Diseases
  3. Comparative Analysis of Methods for Assessing On-Target Gene Editing Efficiencies
  4. RUNX1::RUNX1T1 Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia
  5. Nanoparticle-in-Hydrogel Delivery System for the Sequential Release of Two Drugs
  6. Lipid Nanoparticles for Nucleic Acid Delivery Beyond the Liver
  7. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
  8. Fusogenic Coiled-Coil Peptides Enhance Lipid Nanoparticle-Mediated mRNA Delivery upon Intramyocardial Administration
  9. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery
  10. Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design
  11. Natural or Synthetic RNA Delivery: A Stoichiometric Comparison of Extracellular Vesicles and Synthetic Nanoparticles
  12. Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model
  13. EVQuant; high-throughput quantification and characterization of extracellular vesicle (sub)populations
  14. Delivering the power of nanomedicine to patients today
  15. The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy
  16. Local release of siRNA using polyplex-loaded thermosensitive hydrogels
  17. Drug Delivery with Extracellular Vesicles: From Imagination to Innovation
  18. A head-to-head comparison of conjugation methods for VHHs: random maleimide-thiol coupling versus controlled click chemistry
  19. Development and characterization of liposomal formulation of bortezomib
  20. Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery
  21. Thermosensitive liposomes for triggered release of cytotoxic proteins
  22. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma
  23. Nanomedicines for the treatment of hematological malignancies
  24. Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety
  25. Nanomechanics of Extracellular Vesicles Reveals Vesiculation Pathways
  26. Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting
  27. Cancer cells copy migratory behavior and exchange signaling networks via extracellular vesicles
  28. Squeezing for Life – Properties of Red Blood Cell Deformability
  29. Quantitative measurement of red cell surface protein expression reveals new biomarkers for hereditary spherocytosis
  30. State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery
  31. Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach
  32. Polymers and hydrogels for local nucleic acid delivery
  33. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology
  34. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis
  35. Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative
  36. Tumour-bound RNA-laden exosomes
  37. Microbubbles-Assisted Ultrasound Triggers the Release of Extracellular Vesicles
  38. Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles
  39. In Situ Gelling Liquid Crystalline System as Local siRNA Delivery System
  40. Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction
  41. Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy
  42. Polyphosphate nanoparticles on the platelet surface trigger contact system activation
  43. Clinical application of polymeric micelles for the treatment of cancer
  44. Obstacles and opportunities in the functional analysis of extracellular vesicle RNA – an ISEV position paper
  45. Interaction of Extracellular Vesicles with Endothelial Cells Under Physiological Flow Conditions
  46. Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model
  47. ADDR editorial “Biologically-inspired drug delivery systems”
  48. Extracellular vesicles for drug delivery
  49. Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment
  50. Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention
  51. Head-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In Vitro
  52. Cetuximab treatment alters the content of extracellular vesicles released from tumor cells
  53. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
  54. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting
  55. Lipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency
  56. Silencing of protease-activated receptors attenuates synovitis and cartilage damage following a joint bleed in haemophilic mice
  57. An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs
  58. In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior
  59. Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Π–Π Stacking Stabilized Polymeric Micelles
  60. Possibilities and limitations of current technologies for quantification of biological extracellular vesicles and synthetic mimics
  61. Mechanics of Extracellular Vesicles from Red Blood Cells
  62. Extracellular Vesicles: Potential Roles in Regenerative Medicine
  63. Extracellular vesicles as drug delivery systems: Lessons from the liposome field
  64. Intercalating quaternary nicotinamide-based poly(amido amine)s for gene delivery
  65. EVpedia: a community web portal for extracellular vesicles research
  66. 448 Exposure to EGFR inhibitors influences release of extracellular vesicles by tumor cells
  67. Microparticles as biomarkers of osteonecrosis of the hip in sickle cell disease
  68. Anginex lipoplexes for delivery of anti-angiogenic siRNA
  69. Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma
  70. Hemocompatibility Assessment of two siRNA Nanocarrier Formulations
  71. Toward routine detection of extracellular vesicles in clinical samples
  72. Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation
  73. Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment
  74. Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles
  75. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles
  76. Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways
  77. Trends in polymeric delivery of nucleic acids to tumors
  78. Taxol®-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor®EL
  79. Strategies for triggered drug release from tumor targeted liposomes
  80. Red blood cell: barometer of cardiovascular health?
  81. Extracellular vesicles in the circulation: are erythrocyte microvesicles a confounder in the plasma haemoglobin assay?
  82. Oligonucleotides
  83. Red blood cell vesiculation in hereditary hemolytic anemia
  84. International Society for Extracellular Vesicles: Second Annual Meeting, 17–20 April 2013, Boston, MA (ISEV 2013)
  85. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells
  86. Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation
  87. Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles
  88. 121 Tumor-targeted Nanobullets for Anti-cancer Combination Therapy
  89. MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model
  90. Drug targeting systems for inflammatory disease: One for all, all for one
  91. 1043 Novel Anti-angiogenic MiRNAs Reduce in Vivo Tumor Growth in Mouse Models
  92. Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery
  93. Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis
  94. Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis
  95. Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines
  96. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles
  97. Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin α2β1 receptor
  98. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes
  99. Abstract 1112: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library
  100. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment
  101. Exosome mimetics: a novel class of drug delivery systems
  102. Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies
  103. Liposomes as carriers for colchicine-derived prodrugs: Vascular disrupting nanomedicines with tailorable drug release kinetics
  104. Polyplexes based on cationic polymers with strong nucleic acid binding properties
  105. Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery
  106. Attaching the phage display-selected GLA peptide to liposomes: Factors influencing target binding
  107. Abstract A12: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library
  108. Editorial [ Hot Topic:siRNA Based Approaches in Medicinal Chemistry and Drug Discovery (Guest Editor: Raymond M. Schiffelers )]
  109. Micro-Vesiculation and Disease, London, 13–14 September 2012
  110. Polymeric Carrier Systems for siRNA Delivery
  111. A role for activated endothelial cells in red blood cell clearance: implications for vasopathology
  112. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy
  113. Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression
  114. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: Comparison with stealth liposomes
  115. SiRNA delivery with functionalized carbon nanotubes
  116. Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors
  117. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes
  118. Physicochemical and Biological Evaluation of siRNA Polyplexes Based on PEGylated Poly(amido amine)s
  119. Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach
  120. Neovascular Age-Related Macular Degeneration
  121. Targeted Delivery of Kinase Inhibitors: A Nanomedicine Approach for Improved Selectivity in Cancer
  122. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity
  123. Gene silencing activity of siRNA polyplexes based on biodegradable polymers
  124. Optimization of poly(amido amine)s as vectors for siRNA delivery
  125. The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy
  126. Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity
  127. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain
  128. Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids
  129. Disulfide-Based Poly(amido amine)s for siRNA Delivery: Effects of Structure on siRNA Complexation, Cellular Uptake, Gene Silencing and Toxicity
  130. Gene Silencing Activity of siRNA Polyplexes Based on Thiolated N , N , N -Trimethylated Chitosan
  131. Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental Atherosclerosis
  132. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation
  133. A method for quantifying cellular uptake of fluorescently labeled siRNA
  134. Poly(amido amine) copolymers derived from aminobutanol and ethylene diamine are excellent carriers for siRNA delivery
  135. Photochemical internalization (PCI)-mediated enhancement of gene silencing efficiency of polymethacrylates and N,N,N-trimethylated chitosan (TMC) based siRNA polyplexes
  136. Tumor vasculature as target for therapeutic intervention
  137. In Vivo Methods to Study Uptake of Nanoparticles into the Brain
  138. Liposomes targeting tumour stromal cells
  139. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin
  140. Downregulation of EGFR by a novel multivalent nanobody-liposome platform
  141. Abstract 5485: Modular nanotransporters: a chimeric multi-functional platform for drug deliveryin vivo
  142. Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability
  143. Identification of Peptide Ligands for Targeting to the Blood-Brain Barrier
  144. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies
  145. Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
  146. Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
  147. Targeted Delivery of Anti-Inflammatory Agents to Tumors
  148. Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells
  149. Long circulating biodegradable polymeric micelles: Towards targeted drug delivery
  150. Delivery of siRNA to the Target Cell Cytoplasm: Photochemical Internalization Facilitates Endosomal Escape and Improves Silencing Efficiency, In Vitro and In Vivo
  151. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
  152. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice
  153. Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil
  154. L31 Thermosensitive and biodegradable polymeric micelles with transient stability for targeted drug delivery
  155. Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells
  156. Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice
  157. Antitumor Activity of Liposomal Prednisolone Phosphate Depends on the Presence of Functional Tumor-Associated Macrophages in Tumor Tissue
  158. Therapeutic nanomedicine: Liposomal corticosteroid as targeted antiinflammatory nanomedicine
  159. Utility of Targeted Glucocorticoids in Cancer Therapy
  160. Hydrolysable core-crosslinked thermosensitive polymeric micelles: Synthesis, characterisation and in vivo studies
  161. Oligonucleotides
  162. Targeting the retinal microcirculation to treat diabetic sight problems
  163. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice
  164. Delivery of Nucleic Acids
  165. Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA
  166. Synthetic delivery systems for intravenous administration of nucleic acids
  167. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes
  168. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration
  169. Pharmaceutical Nanocarriers in Treatment and Imaging of Infection
  170. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice
  171. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy
  172. ICS-283: a system for targeted intravenous delivery of siRNA
  173. Silencing Proteins: Nanotechnological Approaches to Deliver siRNA for Cancer Therapy
  174. Targeted Delivery of siRNA
  175. Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer
  176. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis
  177. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
  178. Transporting silence: Design of carriers for siRNA to angiogenic endothelium
  179. Liposomal Targeting of Angiogenic Vasculature
  180. 318. Tumor Growth Inhibition from Tumor Targeted Delivery of Diphtheria Toxin Gene
  181. siRNA-mediated inhibition of angiogenesis
  182. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery
  183. Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice
  184. siRNA as a new drug: intellectual property
  185. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis
  186. Long-Circulating Sterically Stabilized Liposomes in the Treatment of Infections
  187. Inhibition of Ocular Angiogenesis by siRNA Targeting Vascular Endothelial Growth Factor Pathway Genes
  188. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle
  189. Pharmaceutical Prospects for RNA Interference
  190. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
  191. Innovations in liposomal formulations for antimicrobial therapy
  192. Peptide-targeted PEG-liposomes in anti-angiogenic therapy
  193. Innovations in liposomal formulations for antimicrobial therapy
  194. Biodistribution of long-circulating PEG-liposomes in a murine model of established subcutaneous abscesses
  195. Endothelial Cells at Inflammatory Sites as Target for Therapeutic Intervention
  196. LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATURE
  197. LIPOSOME-ENABLED SYNERGISTIC INTERACTION OF ANTIMICROBIAL AGENTS
  198. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies
  199. Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat Klebsiella pneumoniae Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin
  200. Activity of mammalian secreted phospholipase A2 from inflammatory peritoneal fluid towards PEG-liposomes. Early indications
  201. Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models
  202. Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating
  203. Targeting of Antibiotics in Bacterial Infections Using Pegylated Long-Circulating Liposomes
  204. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics
  205. Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice
  206. Diagnostic and Therapeutic Targeting of Infectious and Inflammatory Diseases Using Sterically Stabilized Liposomes
  207. Quantitative Assessment of Aortic Atherosclerosis in APOE*3 Leiden Transgenic Mice and Its Relationship to Serum Cholesterol Exposure
  208. Lipid-Based Formulations for siRNA Delivery